SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more
RECALIBRATE YOUR HEALTHCARE STRATEGY
Learn 4 strategic pivots for 2025 and beyond.
Learn more

Library

| Daily Briefing

Weekly review: The 21 best places to work in health care, according to Glassdoor


The hospitals facing 2021 penalties for hospital-acquired conditions, how Covid-19 vaccines are performing in the real world, and more.

The 21 best places to work in health care, according to Glassdoor (Monday, Feb. 22)

Glassdoor recently released its annual Employees' Choice Awards for the best workplaces in 2021, and the lists include 21 health care and health care-adjacent organizations.

Map: The hospitals facing 2021 penalties for hospital-acquired conditions (Tuesday, Feb. 23)

CMS recently announced that 774 hospitals will face Medicare payment cuts in fiscal year 2021 under Medicare's Hospital-Acquired Condition Reduction Program. See which hospitals were penalized on our interactive map.

What research reveals about California's 'homegrown' coronavirus variant (Wednesday, Feb. 24)

New research suggests that a novel coronavirus variant first identified in California is more contagious than earlier variants of the virus, further raising alarms that new variants circulating in the United States could impede the country's progress in containing its coronavirus epidemic.

Covid-19 vaccines did well in clinical trials. But how about in the real world? (Thursday, Feb. 25)

Early research in the United States, the United Kingdom, and Israel is examining how Covid-19 vaccines perform in real-world settings—and the results offer tantalizing hints about the vaccines' effectiveness after a single dose and against emerging coronavirus variants.

Our 8 biggest questions about Johnson & Johnson's Covid-19 vaccine, answered (Friday, Feb. 26)

FDA on Saturday authorized Johnson & Johnson's coronavirus vaccine for emergency use in the United States, but is the vaccine truly safe and effective? Advisory Board's Brandi Greenberg once again dives deep into the details—including how Johnson & Johnson's vaccine stacks up to Pfizer's and Moderna's vaccines authorized late last year.


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

MORE FROM TODAY'S DAILY BRIEFING

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.